Main > ONCOLOGY (**) > Bladder Cancer>mUC *** > Treatment > USA. B. NivoluMAb

---

USA. B. NivoluMAb's subsections
(*) USA Approval Date: 2017. 02.02.
Company
mUC: Metastatic Urothelial Cancer
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 9
Patent>UpDate: 2018. 10.16.
TradeMark
TradeMark Web-Site

USA. B. NivoluMAb's products
This section has no products